According to statistics, in November, the directors, supervisors and related persons of listed companies in Shanghai and Shenzhen reduced their holdings by a total of about 5.
428 billion yuan, involving 258 companies
.
From the perspective of industry, the amount of reduction in the pharmaceutical and biological industry in November was in the forefront
.
Under the Shenwan industry classification, the amount of reduction in pharmaceutical biology ranked first, about 812 million yuan, followed by the machinery and equipment industry and the power equipment industry, with a reduction amount of about 662 million yuan and 552 million yuan
respectively.
Statistics show that 35 stocks in the pharmaceutical and biological sector experienced significant shareholder reductions in November, among which Kanglong Chemical ranked first
.
In addition, the pharmaceutical and biological companies with the highest reduction amount also include Ruikang Pharmaceutical, Zhaoyan New Drug, Guizhou Sanli, etc.
, all of which have reduced their holdings by more than 50 million yuan
.
It is reported that on November 10, Kanglong Chemical's director and senior management Lou Xiaoqiang reduced their holdings of 2.
150 million shares of the company, accounting for 0.
1805% of the company's
total share capital.
During the change, the company's share price fell 3.
77%, closing at 63.
03 yuan
on November 10.
The average transaction price was 60.
82 yuan per share, reducing its holdings by 131 million yuan
.
In addition, on November 21, Kanglong Chemical issued an announcement "Kanglong Chemical: Announcement on the Completion of the Implementation of the Share Reduction Plan for Shareholders Holding More than 5% of the Shares and Their Concerted Actors and the Results of the Reduction of Shareholding", and its shareholders Beijing Junlian Maolin Equity Investment Partnership (Limited Partnership) and Tianjin Junlian Wenda Equity Investment Partnership (Limited Partnership) reduced their holdings by a total of 11.
6082 million shares from July 15, 2022 to November 18, 2022, accounting for 0.
9746% of the company's current total share capital.
During the change, the stock price fell 30.
33%, closing at 69.
66 yuan
as of November 18.
On November 02, Kanglong Chemical was reduced by Shenzhen Stock Connect by 1.
5134 million shares, and has been reduced by Shenzhen Stock Connect for 8 consecutive days, with a total of 14.
093 million shares, and the latest holding amount is 45.
7235 million shares, accounting for 4.
62%
of the total share capital of the company's A shares.
According to the data, Kanglong Chemical is a full-process integrated pharmaceutical R&D service platform, its main business is divided into four major sectors
: laboratory services, CMC (small molecule CDMO (contract customized R&D and production)) services, clinical research services, macromolecule and cell and gene therapy services.
In the first three quarters of this year, Kanglong Chemical's revenue was 7.
403 billion yuan, a year-on-year increase of 39.
63%; The net profit attributable to the parent was 961 million yuan, down 7.
59%
from the same period last year.
Data show that Ruikang Pharmaceutical's reduction in November was 81.
0231 million yuan
.
Among them, Ruikang Pharmaceutical announced on the evening of November 14 that Ruikang Pharmaceutical Group Co.
, Ltd.
received the "Notification Letter on Reducing Shares through Block Trading" issued by Ms.
Zhang Renhua, the controlling shareholder and actual controller, on November 11, 2022, and Ms.
Zhang Renhua reduced her holdings of 27.
43 million shares of the company through block transactions, accounting for 1.
82%
of the company's total share capital.
After this reduction, Ms.
Zhang Renhua holds 229,538,200 shares of the company, accounting for 15.
25%
of the company's total share capital.
According to the data, Ruikang Pharmaceutical is a pharmaceutical circulation enterprise, providing medical institutions with the distribution business of drugs and medical devices, and the company's subsidiaries are engaged in the production and sales of traditional Chinese medicine pieces
.
Zhaoyan New Drug reduced its holdings in November by about 70.
0883 million yuan
.
Among them, on November 4, Li Ye, the supervisor of Zhaoyan New Drug, reduced his holdings of 1,000 shares of the company through secondary market trading, with an average transaction price of 64.
55 yuan per share, and a reduction of 64,600 yuan
.
In addition, Zhaoyan New Drug also issued an announcement that the company's shareholders Zuo Conglin, Sun Yunxia and Yao Dalin reduced their holdings of 4.
0961 million shares of the company in a concentrated bidding transaction, with a price range of 59.
45-126.
9 yuan per share
.
According to the data, Zhaoyan New Drug has established a gold industry chain with characteristics of drug non-clinical research services, clinical trials and related services, breeding and sales of experimental models and gene editing experimental model customization services, and the company achieved a net profit attributable to shareholders of listed companies of 632,033,151.
04 yuan in the first three quarters, a year-on-year increase of 154.
85%.
Guizhou Sanli reduced its holdings in November by about 69.
1333 million yuan
.
According to the data, Guizhou Sanli is a modern proprietary Chinese medicine pharmaceutical enterprise
integrating R&D, production and sales.
The company's product line mainly focuses on pediatrics, respiratory system, cardiovascular and cerebrovascular medicine, gastroenterology and other fields, the main products are throat opening sword spray (children's type), throat opening sword spray and powerful gastronoma eucommia capsules
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
